Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist

ConditionLaxity; Skin
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age45-65
SponsorGoldman, Butterwick, Fitzpatrick and Groff

About this trial

The primary objective is to assess the safety and efficacy of the AGE Serum in improving the appearance of skin in post-menopausal subjects on HRT and non-HRT who are takingGLP-1 agonist therapy through the use of investigator assessments, subject questionnaires/assessments, photography, skin imaging, and reported adverse reactions.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Post-menopausal women (25 on HRT, 25 non HRT all must be post-menopausal)

Presence of mild to moderate signs of facial aging (e.g., fine lines, laxity, dull texture) based on modified Griffith scale.

Adult women aged 45-65 years.

Fitzpatrick skin types I-VI.

Disqualifiers

Non post-menopausal state.

Any uncontrolled systemic disease.

History of autoimmune connective tissue disease.

Current use of immunosuppressive medication.

Trial design

Design model

Parallel

Treatments tested in this trial

  • On GLP1 plus HRT

    Drug

    AGE serum is a topical that contains a high concentration of 30% Proxylane and a synergistic blend of fruit-derived flavonoids (blueberry, pomegranate) and Cassia alata extract.

  • On GLP1 Only

    Drug

    AGE serum is a topical that contains a high concentration of 30% Proxylane and a synergistic blend of fruit-derived flavonoids (blueberry, pomegranate) and Cassia alata extract.

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Group A= On GLP1 plus HRTActive comparator 1 intervention
Group B: Group B= On GLP1 OnlySham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Modified Griffith Scale

Modified Griffiths 10-point scale to be used for investigator grading of cutaneous signs of photoaging on the face. Global Fine Lines. Scale 0 (no fine lines) to 9 (numerous, many fine lines) Overall Hyperpigmentation: Scale 0 (no hyperpigmentation) to 9 (significant hyperpigmentation) Skin Tone Eveness: Scale 0 (very even tone) to 9 (uneven, discolored appearance) Skin Elasticity: Score 0 (skin feels toned and dense) to 9 (skin feels thin and flabby) Skin Firmness: Score 0 (firm, tight feeling) to 9 (loose, lax feeling) Skin Radiance: Score 0 (very radiant, luminous, glowing) to 9 (very dull) Skin Texture: Score 0 (very smooth) to 9 (very rough)

Time frame
Baseline, Week 6 and Week12

Secondary outcomes

1

Physician Global Aesthetic Improvement Scale

Physician Grading: 1. Very Much Improved 2. Much Improved 3. Improved 4. No Change 5. Worse

Time frame
Week 12
2

Subject Global Aesthetic Improvement Scale

Subject Grading: 1. Very Much Improved 2. Much Improved 3. Improved 4. No Change 5. Worse

Time frame
Week 12
3

Subject Self-Assessment Questionnaire

Circle One Skin Feels More Comfortable: Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly Skin Appears Younger Looking: Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly Skin Appears Healthier: Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly Skin Looks Renewed/Revitalized: Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly Skin Looks Firmer: Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly Skin Feels Elastic : Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly Redness Looks Reduced: Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly

Time frame
Baseline, Week 6 and Week 12

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: